Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ahn has already lost a lot of value in his own investment with USRM. Something like 98% of the value of the stock he bought last year is now gone.
Maybe he's just given up?
Maybe he no longer wants to have his name associated with the company?
It's very strange after those insider buys from last year...why did he make those purchases and then a half year later resign and dissociate himself from the company's BOD?
When the 10Q is released, there may be some clues in what is or isn't disclosed. I'll be paying particular attention to the disclosures of related party transactions.
just my questions and speculation.
It's an interesting theory.
Clearly they're slow playing the release of the investigative report.
NW is purely a financial investors who didn't even ask for board seats during his last round of stock purchases. So, I'm not sure Linda has to really play chess with NW, if in fact his fund is restricted from buying more shares due to the none release of the IR. And given his stake in the company, NW could be heavy handed if he really wanted w/o the niceties of a board game. He seems content on the sidelines not making any waves, so who knows?
It's a bad sign that Ahn resigned.
I would like to speak with him to find out why?
Yeah, management has played this very poorly.
I very much doubt there's anything found during the investigation that necessarily needs to be disclosed for legal reasons, so there's some comfort in that. But since they did a formal investigation, the lawyers probably found some transactions/disclosures that were less than satisfactory, and may need to be disclosed in a 10Q. So maybe, they're slow playing the investigation and its release for that reason?
But the worst part is the level of uncertainty this has created, which has played straight into the hands of the bad actors that have maligned this company. Although many of the problems are not directly the fault of management, I do believe they've severally compounded the problems - just my humble opinion.
No way a company with a late phase III cancer treatment and pending Big Pharma collaborations/JVs should be sitting on a market cap < $50 million. No way.
Just don't understand what Linda Powers is afraid of?
There needs to be some communication with shareholders that provides clarity on where everything stands with the company's financial, regulatory and business progress, without risking compliance with FDA and SEC requirements.
Maybe there's some legal risk (in her own mind) about offering any guidance, but that potential cost is relatively small compared with the cost to shareholders due to the rapid decline in the stock price.
Power's inaction just doesn't make much sense.
These past capital raises have been a disaster for shareholders.
The structure of these deals with the placement of discounted shares along with warrants has led to a precipitous decline in the stock price, well beyond the percentage of the dilution. I find it hard to believe in the last round that participating investors didn't sell their shares, just based on the increase in volume following the effective date and the immediate decline in the stock price.
The effect of these capital raises is like watching a nail being hammered. The nail is stuck in place and is then hit further down with each consecutive blow, without any bounce.
If management believes there is some probability this will drag on much longer, then they seriously need to be speaking with potential buyers. Otherwise, the $10 per share target price will turn into $3 or $4 when all the dilution is taken into considerations.
The staff at the FDA needs to get off their duffs.
The FDA is slow and subject to outside influences. There has to be a better way to manage drug approvals. NWBO appears to be a looming case study of how the FDA simultaneously deters investment in biotech and slows the treatment and prematurely kills patients by how they implement policy for drug approvals..
http://www.fdareview.org/05_harm.php
Maybe some of the experts can weight in, but it just appears to me that the FDA seems to do more harm than good with these halts. It just seems to me that patients would have more options for treatment, and there would be less pain and suffering, if the FDA were not so punitive in how they respond when an issue comes up in a trial.
I would like to hear from anyone on this board that has worked with or for the FDA, just to get a sense of whether there are some systemic problems at the agency. There just has to be a better way forward with drug approvals.
I could tell a couple of things that are very frustrating. The first is the company has found itself in bureaucratic limbo, which makes matters very uncertain in ways that are unimaginable. And as an aside, it's one of the reasons why I thought/think that Linda needs to explore the possibility of selling NWBO, just given the level of uncertainty.
The second thing I know is Biden would not make much, if any, difference. Although from time to time Biden can get down in the weeds -- and that was my hope -- he's generally ineffectual. And the moonshot is increasing looking like the hot air balloon tour - like that festival that goes on in New Mexico every year.
This is a stunner...
Nice work HD.
Since Tomas also made the list, he also has (or should have) full knowledge of this potential conflict of interest and non-disclosure. And there is a picture of Murphy speaking at one of their conferences, so that makes a third director that should have knowledge of this potential conflict. Not only do they have knowledge, but it seems they're actively participating in the academy's events. Wow.
It would be interesting to understand whether the other directors have knowledge of this as well?
In asking the question: "How can esteemed scientists such as Atala and Gage be ranked so poorly on the top 50 list," the answer is that the Top 50 list is just a popularity contest for whomever receives the most votes from folks on their contact list.
Read the description below from the World StemCell Congress web site for 2013. It clearly states the vote could be based on nearly anything, such as whether you believe someone is "dedicated" or "inspires others to do well." If that's not vague enough, I'm not sure what is?
Clarification:
I meant to say in the quote below that the picture shows one of the two clinics where the study was performed. The hospital in Tijuana, Mexico was the other clinic that participated. Dr. H. Bansal, who is attempting to revive the dead at the clinic in India, is also a co-author of the USRM study,
The NIH article is from 2008.
Below is an article from a newspaper in India that shows a picture of the hospital and features the doctor that co-authored USRM's recent study.
http://www.thehindu.com/news/national/a-strange-project-to-revive-the-brain-dead/article8601787.ece
That looks like a fairly rogue hospital and rogue doctor to me. Unless raising the dead is considered legitimate science?
From the Canadian Broadcast Corporation:
http://www.cbc.ca/news/health/stem-cell-clinics-1.3663955
And U.S. STEM CELL is very involved with a stem cell clinic in Tijuana, Mexico. (Although don't know from the article if it's the same one as referenced in the quote below.)
Very interesting, indeed.
Powerful Statement...I wish the FDA would understand this and respond with more urgency.
Not too on-board with the role of shorts in the recent volume and price movement. Shorts play various roles in the investment landscape and they tend not to be as critical in the movement of stock prices as much as it might seem.
I do believe those funds tied to the Russell Indexes were anticipating they would have to sell their holdings of NWBO, they were making deals with buyers for large volumes at very low asks. That's the likely reason why this stock has gone so low. Expect that the stock has stabilized and is so over-sold, we should see a nice bounce.
We live in interesting times.